Biome Grow Inc., through its subsidiaries, cultivates, produces, and distributes cannabis at Antigonish, Nova Scotia. More Details
Overvalued with worrying balance sheet.
Share Price & News
How has Biome Grow's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIO is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 36% a week.
Volatility Over Time: BIO's weekly volatility has increased from 30% to 36% over the past year.
7 Day Return
1 Year Return
Return vs Industry: BIO underperformed the Canadian Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: BIO underperformed the Canadian Market which returned -1.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Biome Grow's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 months ago | Simply Wall StWhat Type Of Shareholder Owns Biome Grow Inc.'s (CSE:BIO)?
11 months ago | Simply Wall StCan We See Significant Insider Ownership On The Biome Grow Inc. (CSE:BIO) Share Register?
1 year ago | Simply Wall StDo Insiders Own Lots Of Shares In Biome Grow Inc. (CNSX:BIO)?
Is Biome Grow undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BIO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BIO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BIO is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: BIO is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIO is good value based on its PB Ratio (0.8x) compared to the CA Pharmaceuticals industry average (1.5x).
How is Biome Grow forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biome Grow has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of BIO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Biome Grow competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Biome Grow performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIO is currently unprofitable.
Growing Profit Margin: BIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIO is unprofitable, and losses have increased over the past 5 years at a rate of 62.9% per year.
Accelerating Growth: Unable to compare BIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-19.7%).
Return on Equity
High ROE: BIO has a negative Return on Equity (-240.16%), as it is currently unprofitable.
How is Biome Grow's financial position?
Financial Position Analysis
Short Term Liabilities: BIO's short term assets (CA$4.3M) do not cover its short term liabilities (CA$6.3M).
Long Term Liabilities: BIO's short term assets (CA$4.3M) exceed its long term liabilities (CA$1.5M).
Debt to Equity History and Analysis
Debt Level: BIO's debt to equity ratio (69.1%) is considered high.
Reducing Debt: Insufficient data to determine if BIO's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BIO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.8% each year
What is Biome Grow current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIO's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Khurram Malik, MBA, serves as Chief Executive Officer and Director at Biome Grow Inc. since October 03, 2018. Mr. Malik serves as the President of Biome Grow Inc. He was a Clean Technology Analyst at J...
CEO Compensation Analysis
Compensation vs Market: Khurram's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD164.99K).
Compensation vs Earnings: Insufficient data to compare Khurram's compensation with company performance.
|CEO, President & Director||2.08yrs||CA$86.90k||2.67% |
|Independent Director||2.08yrs||CA$160.00k||no data|
|Independent Director||2.08yrs||CA$160.00k||no data|
Experienced Board: BIO's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biome Grow Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Biome Grow Inc.
- Ticker: BIO
- Exchange: CNSX
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$3.373m
- Shares outstanding: 112.42m
- Website: https://www.biomegrow.com
- Biome Grow Inc.
- 480 University Avenue
- Suite 1401
- M5G 1V2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIOI.F||OTCPK (Pink Sheets LLC)||Yes||New Common Shares||US||USD||Oct 2018|
|BIO||CNSX (Canadian National Stock Exchange)||Yes||New Common Shares||CA||CAD||Oct 2018|
|6OTA||DB (Deutsche Boerse AG)||Yes||New Common Shares||DE||EUR||Oct 2018|
Biome Grow Inc., through its subsidiaries, cultivates, produces, and distributes cannabis at Antigonish, Nova Scotia. The company is headquartered in Toronto, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/24 23:37|
|End of Day Share Price||2020/11/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.